New program seeks solutions to health impacts of high-THC products

Cannabis legalization in WA state brought a flurry of manufactured products that contain highly concentrated tetrahydrocannabinol (THC), the cannabinoid responsible for cannabis' mind-altering effects. In response, the University of Washington's Addictions, Drug & Alcohol Institute (ADAI) has been contracted by the Washington Health Care Authority (mandated by ESSB 5092) to explore and suggest policy solutions to the public health challenges associated with high-THC products. The ADAI team seeks to include the perspectives and preferences of tribal partners within WA state who may be affected by such policies. The ADAI team will introduce the project at the January Monthly Tribal Meeting (MTM) to learn how to engage/include tribal partners. For more information about the project contact Beatriz Carlini, at bia@uw.edu. For more information on the health impacts of high-THC products, a summary report can be found on the ADAI webpage.